Celularity Inc: Unternehmensprofil, Finanzberichte & Marktperformance

mehr Informationen über Celularity Inc Unternehmen

Celularity Inc. is a regenerative and cellular medicine company. The Company is developing and commercializing advanced biomaterial products and allogeneic, cryopreserved, placental-derived cell therapies, all derived from the postpartum placenta. Its therapeutic programs target aging-related diseases, including degenerative diseases, cancer, and immune disorders, using mesenchymal-like adherent stromal cells, T-cells engineered with CAR (CAR T-cells), and genetically modified and unmodified natural killer (NK) cells. It develops, manufactures and commercializes advanced biomaterial products derived from structural tissue components of the postpartum placental tissues, including the umbilical cord. Its advanced biomaterials include Celularity Tendon Wrap, FUSE Bone Void Filler and Celularity Placental Matrix. Its advanced biomaterial products include Biovance, Biovance 3L, CentaFlex, Interfyl and Rebound products.

Celularity Inc Informationen



BörsenkürzelCELU

Name des UnternehmensCelularity Inc

IPO-datumMay 23, 2019

CEOHariri (Robert J)

Anzahl der mitarbeiter123

WertpapierartOrdinary Share

GeschäftsjahresendeMay 23

Addresse170 Park Ave

StadtFLORHAM PARK

BörseNASDAQ OMX - NASDAQ BASIC

LandUnited States of America

Postleitzahl07932

Telefon19087682170

Websitehttps://celularity.com/

BörsenkürzelCELU

IPO-datumMay 23, 2019

CEOHariri (Robert J)

Führungskräfte von Celularity Inc



Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+3281.00%

Mr. Vincent Levien

Independent Director

157.55K

+28847.00%

Dr. Peter H. Diamandis, M.D.

Independent Director

--

Ms. Diane L. Parks

Independent Director

--

Mr. Stephen A. Brigido

President - Degenerative Disease

--

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

--

Dr. Shiu Fei (Geoffrey) Ling, M.D., Ph.D.

Independent Director

--

Mr. Carlos Ramirez

Senior Vice President - Investor Relations

--

Mr. Joseph Dossantos

Interim Chief Financial Officer

--

Name

Name/Position

Position

Aktienbesitz

Veränderung

Dr. Robert J. (Bob) Hariri, M.D., Ph.D.

Chairman of the Board, Chief Executive Officer

2.86M

+3281.00%

Mr. Vincent Levien

Independent Director

157.55K

+28847.00%

Dr. Peter H. Diamandis, M.D.

Independent Director

--

Ms. Diane L. Parks

Independent Director

--

Mr. Stephen A. Brigido

President - Degenerative Disease

--

Mr. John R. Haines

Senior Executive Vice President, Chief Administrative Officer, Corporate Secretary

--

Umsatzaufteilung

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Nach Geschäftsbereich

Nach Region

Relevante Daten wurden vom Unternehmen noch nicht offengelegt.

Aktionärsstatistik

Aktualisiert: Sat, Jan 3

Aktionäre

Aktionärstypen

Aktionäre

Anteil

Genting Bhd

21.97%

Hariri (Robert J)

9.91%

Starr International Company, Inc.

5.30%

Lincoln Alternative Strategies LLC

4.27%

C.V. Starr & Co., Inc.

2.65%

Andere

55.90%

Aktionäre

Anteil

Genting Bhd

21.97%

Hariri (Robert J)

9.91%

Starr International Company, Inc.

5.30%

Lincoln Alternative Strategies LLC

4.27%

C.V. Starr & Co., Inc.

2.65%

Andere

55.90%

Aktionärstypen

Aktionäre

Anteil

Corporation

26.24%

Individual Investor

15.43%

Investment Advisor

8.72%

Insurance Company

2.65%

Investment Advisor/Hedge Fund

1.30%

Hedge Fund

0.38%

Research Firm

0.17%

Family Office

0.04%

Andere

45.07%

Institutionelle Beteiligung



Aktualisiert: Mon, Dec 8

Berichtszeitraum

Anzahl der Institutionen

Gehaltenen Aktien

Anteil

Veränderung

2025Q4

71

3.82M

13.73%

--

2025Q3

80

3.82M

16.36%

+119.97K

2025Q2

92

3.70M

17.46%

+189.07K

2025Q1

120

3.51M

18.18%

-579.52K

2024Q4

135

3.39M

17.70%

+120.20K

2024Q3

149

3.27M

18.60%

+20.75K

2024Q2

160

3.32M

18.56%

+109.90K

2024Q1

166

3.20M

18.29%

-780.71K

2023Q4

164

3.20M

20.76%

-511.70K

2023Q3

164

3.71M

20.21%

+96.25K

Aktionärsaktivitäten



Name

Gehaltenen Aktien

Anteil

Veränderung

Änderung%

Datum

Genting Bhd

6.34M

22.25%

--

Oct 30, 2025

Hariri (Robert J)

2.86M

10.04%

+3.28K

+0.11%

Oct 30, 2025

Starr International Company, Inc.

1.53M

5.37%

--

Oct 30, 2025

Lincoln Alternative Strategies LLC

1.23M

4.32%

+1.23M

--

Jul 14, 2025

C.V. Starr & Co., Inc.

764.07K

2.68%

--

Sep 30, 2025

The Vanguard Group, Inc.

676.65K

2.38%

+176.52K

+35.29%

Sep 30, 2025

Ling (Geoffrey M. D.)

472.29K

1.66%

+192.42K

+68.75%

Dec 29, 2025

Diamandis (Peter)

441.18K

1.55%

+192.42K

+77.35%

Dec 29, 2025

Parks (Diane L.)

344.98K

1.21%

+192.42K

+126.12%

Dec 29, 2025

Levien (Vincent)

128.70K

0.45%

+125.00K

+3379.29%

Dec 29, 2025

Verbundene ETFs



Aktualisiert: Sat, Dec 6

Name

Anteil

iShares Micro-Cap ETF

0%

DFA Dimensional US Sustainability Core 1 ETF

0%

iShares Micro-Cap ETF

Anteil0%

DFA Dimensional US Sustainability Core 1 ETF

Anteil0%

Dividende



In den vergangenen 5 Jahren wurden insgesamt 0.00 USD an Dividenden ausgeschüttet.

Datum

Dividende

Stichtag für die Aktienregistrierung

Zahltag

Ex-Dividendentag

Keine Daten

Aktien-Split



Datum

Ex-Dividendentag

Art

Verhältnis

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Datum

Ex-Dividendentag

Art

Verhältnis

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1

Feb 23, 2024

Merger

10→1